RxDoctor Payments Data

David Williams

Pediatric Hematology-Oncology · Boston, MANPI 1871658682

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,945 of the $10,963 with a category attached, or 99.8%. Vertex accounts for 80.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $8,820 and has fallen 75.9% since, to $2,125 in 2025.

$10,963in general payments, 2019–2025

Across 3 payments — averaging $3654.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$9K
  • Astrazeneca UK Limited$2K
  • Novartis$18
$711,947in research payments, 2019–2025

Across 7 payments — averaging $101,707 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • National Marrow Donor Program$572K
  • Genetix Biotherapeutics Inc$140K
  • Novartis$477

What the payments were for

  • Consulting fees$10,945100%
  • Food & beverage$180%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex1$8,820
Astrazeneca UK Limited1$2,125
Novartis1$18

How this compares

$10,963 in reported general payments places this provider in the 75th percentile of 114 pediatric hematology-oncology providers in Massachusetts.

See all pediatric hematology-oncology providers in Massachusetts

Other pediatric hematology-oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →